Joelle P. Hamilton

Oncology
2000 6th Ave S
Birmingham, AL 35233

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Journal: JAMA network open
Published: August 19, 2026

Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial.

Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial.

Journal: BMC cancer
Published: September 23, 2025

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Journal: Prostate cancer and prostatic diseases
Published: June 11, 2025

Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States.

Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States.

Journal: Urology practice
Published: May 28, 2025

Using darolutamide in advanced prostate cancer: How I Do It.

Using darolutamide in advanced prostate cancer: How I Do It.

Journal: The Canadian journal of urology
Published: June 15, 2021
Showing 1-5 of 5

Last Updated: 09/26/2026